Lomedeucitinib vs TQH3906

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

Lomedeucitinib

Developed by Beeline Medicines under a licence from Bristol-Myers Squibb

Phase 2 in Psoriasissmall molecule
Partial signal

NCT05730725 · Phase 2 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.

Reported efficacy

Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks); Number of Participants With Safety Related Events (approximately 85 days); Number of Participants With TEAE by Worst Intensity (approximately 5 months); Number of Participants With AE Indicating Clinical Laboratory Abnormality (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in ECG Evaluations. (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Evaluations (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Evaluations (approximately 5 months): Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks): BMS-986322 16 mg 47.8% (95% CI 26.8 to 69.4) | BMS-986322 32 mg 80.8% (95% CI 60.6 to 93.4) | BMS-986322 64 mg 63% (95% CI 42.4 to 80.6) vs Placebo 3.6% (95% CI 0.1 to 18.3) (met)

Result source: NCT05730725

TQH3906

Developed by Sino Biopharmaceutical

Phase 3 in PsoriasisSmall molecule (oral TYK2 inhibitor)
Partial signal

NCT06542614 · Phase 2 · completed

This Phase 2 trial randomly assigned 209 people with plaque psoriasis to TQH3906 or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was the proportion reaching PASI 75, a 75% improvement in psoriasis severity, at week 12. The sponsor reports more than 90% reaching PASI 75 and more than 70% reaching PASI 90 at the recommended dose, but gives no placebo figure and no statistical comparison, so the size of the advantage over placebo is not established by what has been released.

Next expected readout: September 2027 · NCT07724366 (registry estimate)

Reported efficacy

Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 at week 12 (Up to week 12): At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks (met)

Result source: NCT06542614

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLomedeucitinibTQH3906
PASI 7563% vs 3.6%+59.4 vs placebowk 12 · n 27NCT05730725
17 other results
  • 80.8% vs 3.6% wk 12 · n 26 · Phase 2 · primary NCT05730725
  • 47.8% vs 3.6% wk 12 · n 23 · Phase 2 · primary NCT05730725
  • 72% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 57.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 4% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 3.8% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 80.8% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 66.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 33.3% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 11.5% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 54.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 40% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.4% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
—Trial running · NCT07724366
PASI 9040.7% vs 3.6%+37.1 vs placebowk 12 · n 27NCT05730725
17 other results
  • 48% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 61.5% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 61.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 25.9% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 18.5% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 13% vs 3.6% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 13.6% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
—Trial running · NCT07724366
PASI 1003.7% vs 0%+3.7 vs placebowk 12 · n 27NCT05730725
17 other results
  • 4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
—Trial running · NCT07724366
sPGA 0/155.6% vs 3.6%+52 vs placebowk 12 · n 27NCT05730725
2 other results
  • 69.2% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 54.2% vs 3.6% wk 12 · n 24 · Phase 2 · secondary NCT05730725
—Trial running · NCT07724366
DLQI, change—Not reported—Trial running · NCT07724366

PASI 75

Lomedeucitinib
63% vs 3.6%+59.4 vs placebowk 12 · n 27NCT05730725
17 other results
  • 80.8% vs 3.6% wk 12 · n 26 · Phase 2 · primary NCT05730725
  • 47.8% vs 3.6% wk 12 · n 23 · Phase 2 · primary NCT05730725
  • 72% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 57.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 4% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 3.8% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 80.8% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 66.7% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 33.3% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 11.5% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 54.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 40% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.4% vs 3.6% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
TQH3906
—Trial running · NCT07724366

PASI 90

Lomedeucitinib
40.7% vs 3.6%+37.1 vs placebowk 12 · n 27NCT05730725
17 other results
  • 48% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 30.8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 7.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 61.5% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 61.5% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 25.9% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 18.5% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 13% vs 3.6% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 13.6% vs 4.2% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 8% vs 4% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
TQH3906
—Trial running · NCT07724366

PASI 100

Lomedeucitinib
3.7% vs 0%+3.7 vs placebowk 12 · n 27NCT05730725
17 other results
  • 4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 15.4% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 3.7% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 23 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 12 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 8 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 4 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 2 · n 27 · Phase 2 · secondary NCT05730725
  • 0% vs 0% wk 1 · n 27 · Phase 2 · secondary NCT05730725
TQH3906
—Trial running · NCT07724366

sPGA 0/1

Lomedeucitinib
55.6% vs 3.6%+52 vs placebowk 12 · n 27NCT05730725
2 other results
  • 69.2% vs 3.6% wk 12 · n 26 · Phase 2 · secondary NCT05730725
  • 54.2% vs 3.6% wk 12 · n 24 · Phase 2 · secondary NCT05730725
TQH3906
—Trial running · NCT07724366

DLQI, change

Lomedeucitinib
—Not reported
TQH3906
—Trial running · NCT07724366
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

TQH3906
At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks NCT06542614 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lomedeucitinib: 3 of 4 rows · TQH3906: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLomedeucitinib
Dropout rate
7.4%BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
3.7%BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7%BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Discontinued due to AEs
—BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
—BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
—BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Serious AEs
0%BMS-986322 64 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
0%BMS-986322 32 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7%BMS-986322 16 mg
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
Most frequent reported AEs
acne 14.8% (placebo 0%)
covid-19 11.1% (placebo 0%)
dermatitis acneiform 7.4% (placebo 0%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
aphthous ulcer 11.1% (placebo 0%)
folliculitis 11.1% (placebo 0%)
upper respiratory tract infection 7.4% (placebo 0%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
diarrhoea 7.4% (placebo 0%)
headache 7.4% (placebo 0%)
influenza 7.4% (placebo 3.6%)
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lomedeucitinib

PASI 75 63% (n=27) vs 3.6% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
3.8% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
4% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
30.8% (n=27) vs 3.6% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
57.7% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
72% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
80.8% (n=26) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
11.5% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
33.3% (n=27) vs 3.6% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
66.7% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
80.8% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
47.8% (n=23) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.4% (n=27) vs 3.6% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
40% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
54.5% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
sPGA 0/1 55.6% (n=27) vs 3.6% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 2 more results
69.2% (n=26) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
54.2% (n=24) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 50 81.5% (n=27) vs 17.9% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
7.7% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
24% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
65.4% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
88.5% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92.3% (n=26) vs 17.9% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.7% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
34.6% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
66.7% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
85.2% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
92.3% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
73.9% (n=23) vs 17.9% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.8% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
14.8% (n=27) vs 12% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
48.1% (n=27) vs 10.7% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
84% (n=27) vs 8% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
81.8% (n=27) vs 20.8% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 90 40.7% (n=27) vs 3.6% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
7.7% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
30.8% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
48% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
61.5% (n=26) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
18.5% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
25.9% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
61.5% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
13% (n=23) vs 3.6% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
8% (n=27) vs 4% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
13.6% (n=27) vs 4.2% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI 100 3.7% (n=27) vs 0% (n=28) placebo @ 12wk
responder rate · % of participants
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 17 more results
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
4% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
15.4% (n=26) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
3.7% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
15.4% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=23) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
0% (n=27) vs 0% (n=28) placebo @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
PASI -3.36 vs -0.5 placebo score @ 1wk
absolute change · score
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
show 14 more results
-6.27 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.05 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.06 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.44 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-2.95 vs -0.5 placebo score @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-7.13 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-10.63 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.66 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-15.39 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-2.85 vs -0.5 placebo score @ 1wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-5.16 vs -3.3 placebo score @ 2wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-8.53 vs -3.97 placebo score @ 4wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-13.34 vs -3.73 placebo score @ 8wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2
-14.55 vs -4.43 placebo score @ 12wk
NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lomedeucitinib's landscape · TQH3906's landscape